What is Fel d 1?
Fel d 1 (Felis domesticus allergen 1) is the primary cat allergen, responsible for the majority of cat-related allergic reactions. It is a small (36 kDa), unusually stable glycoprotein produced primarily by sebaceous and salivary glands. Cats deposit it on their fur during grooming, from where it becomes airborne on microscopic dander particles small enough to remain suspended in air for extended periods and penetrate deep into the respiratory tract.
Its extraordinary persistence is part of what makes cat allergy so problematic: Fel d 1 is detectable in environments months after a cat has been removed, in schools and offices where cats have never been present (transported on clothing), and even in hospital settings. An open-access molecular review is available in Frontiers in Allergy (2021).
The hypoallergenic breed myth
No cat breed produces zero Fel d 1. The "hypoallergenic" label applied to Siberians, Balinese, Sphynx, and other breeds is not supported by systematic evidence. A 2019 study in the Journal of Allergy and Clinical Immunology found no consistent breed-level difference in Fel d 1 production — individual variation within a breed is greater than variation between breeds.
Factors that do affect Fel d 1 levels in individual cats: intact males produce more than neutered males; females generally produce less; coat length correlates with surface allergen distribution but not production levels; and individual genetics play a significant role that cannot currently be selected for in breeding.
New approaches targeting the cat
Allergen-neutralising diet (Purina Pro Plan LiveClear)
Contains egg-derived anti-Fel d 1 antibodies that bind to Fel d 1 in the cat's saliva before it is deposited during grooming. A peer-reviewed trial (Satyaraj et al., 2019, JACI: In Practice) reported approximately 47% reduction in active Fel d 1 on hair and dander after 3 weeks of exclusive feeding. Does not eliminate the allergen but may provide meaningful reduction for sensitive individuals.
HypoCat vaccine
A vaccine that stimulates the cat's immune system to produce anti-Fel d 1 antibodies, neutralising the allergen before it reaches the environment. Phase I/II trials showed significant reduction in active Fel d 1 levels in immunised cats. Still in clinical development (as of 2026) and not yet commercially available. Research published in Journal of Allergy and Clinical Immunology (Grönlund et al., 2020).
CRISPR-based approaches
Early-stage research has explored using gene editing to reduce or eliminate Fel d 1 production in cats, since the protein appears to serve no essential function in the cat itself. A 2020 paper in Frontiers in Allergy analysed the feasibility of this approach. Still in early research stages; no commercial application is imminent.
Currently most effective strategies. HEPA air filtration, keeping cats out of bedrooms, and regular washing of the cat (weekly, with water) can each meaningfully reduce allergen exposure. Combined with the Pro Plan LiveClear diet, these measures can allow many sensitised individuals to live comfortably with cats while immunotherapy is considered. Consult an allergist for individual assessment.
For people considering cat allergy immunotherapy
Allergen immunotherapy (desensitisation) — either subcutaneous (injection) or sublingual (under-tongue drops/tablets) — is the only treatment that modifies the allergic response itself rather than managing symptoms. It involves gradual exposure to increasing amounts of cat allergen over months to years. It is effective for a substantial proportion of people with cat allergy and may be appropriate for those who plan to live with cats long-term.
The British Society for Allergy and Clinical Immunology and American Academy of Allergy, Asthma & Immunology (AAAAI) both publish patient guidance on the allergen immunotherapy process.